Default company panoramic image

EpiQi Sciences

EpiQi will reposition an FDA approved drug to treat Anemia of Chronic Inflammation, a condition afflicting 135 million people in the US.

  • Stage Product In Development
  • Industry Healthcare Services
  • Location Provo, UT, USA
  • Currency USD
  • Employees 3

Company Summary

EpiQi [Ep-u-chee] Sciences is a drug repositioning firm formed to reposition an already FDA approved drug from its existing disease to treat anemia of chronic inflammation (ACI). After a projected 3 year window to complete repositioning, EpiQi Sciences will license its patent rights to pharmaceutical companies and collect royalties over an extended 20-year patent life.


  • Default avatar
    Jon Miller
    Chief Executive Officer

    Jon Miller is a successful entrepreneur from the Seattle area.

  • Default avatar
    Dean Allan Graham
    Chief Operating Officer

    Dean Graham is an MBA student at BYU. He has recruited the management team, written the business plan material, and secured an option on the technology license from BYU.

  • Default avatar
    Houda Hachad
    Chief Science Officer

    Houda Hachad is an entrepreneurial scientist who has licensed technologies from the University of Washington.


  • Default avatar
    Patent work done through BYU Technology Transfer Office